Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K, van der Wel TJWT, Zeverijn LJ, Geurts BS, Spiekman IAC, de Wit GF, Roepman P, Jansen AML, van der Noort V, Smit EF, Hoeben A, Hendriks LEL, van den Heuvel MM, Piet B, Herder GJM, Hashemi SMS, Gelderblom H, Verheul HMW, Voest EE, de Langen AJ.
Verkerk K, et al. Among authors: de langen aj.
Clin Cancer Res. 2024 Dec 2;30(23):5323-5332. doi: 10.1158/1078-0432.CCR-24-1925.
Clin Cancer Res. 2024.
PMID: 39352721
Clinical Trial.